Vaxcyte (PCVX)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Vaxcyte Analyst Rating
View moreForecast & Rating
Sep 4, 2026Price forecast
$109.0087.51%
Forecast & RatingStrong buy
11analysts
- Strong buy81.82%
- Buy9.09%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Sep 12 at 04:36 AM
Vaxcyte (PCVX) On Tighter Phase 3 Timing And New Hires Looks Undervalued
- Market Beat · Sep 9 at 11:08 PM
Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock
- PUBT · Sep 9 at 09:47 PM
Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil disposes of common shares worth $493,376.94
- PUBT · Sep 9 at 09:33 PM
Vaxcyte files Form 3 disclosing Chief Medical Officer Luis Jodar stake
- Global Report · Sep 9 at 10:11 AM
M&A and Cash Runways Drive Action Across Fringe Equities
- Simplywall · Sep 6 at 12:26 AM
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX)
